Mark O’Connor

Company: AstraZeneca

Job title: Chief Scientist, Oncology R&D, Head of the DNA Damage Response Strategic Biology Area

Seminars:

Panel Discussion: What’s Next for DDR Therapeutics? Evaluating Next-Gen PARP Inhibitors, Novel Targets, & the Future of Clinical Validation 4:15 pm

How are biopharma validating novel DDR targets, and what role will next-gen PARP inhibitors play in the evolving landscape of DDR therapeutics? What preclinical frameworks are currently in use for DDR inhibitors, and how can they be enhanced to better predict clinical success and viability? As we look to the future, could expanding data access—such…Read more

day: Day Two

Combining PARP & Androgen Receptor Inhibitors in Prostate Cancer: New Insights into the Mechanism of Action 10:30 am

Explore the interplay between PARPi and AR inhibition in preclinical prostate cancer models and the mechanism of action providing combination activity beyond HRD prostate cancer Review of the DNA repair role of AR and regulation by PARP1 and the induction of DNA damage and genomic instability from combination treatment Discuss how these insights provide a…Read more

day: Day One